GBS Inc.

Greetings, and welcome to the GBS, Inc. Third Quarter 2022 Earnings Conference Call. Currently, all participants are on listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. Joining us on the call today from the company are Dr. Stephen Boyages, Interim CEO and Chairman of the Board, and Spiro Securis, Chief Financial Officer. A press release announcing the results and the update was issued this afternoon and is available now on the GBS website. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to investor.relations at gbs.inc. Some of the statements on this conference call are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements on this call include, without limitation, GPS Inc.' 's ability to develop and commercialize its diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although GBS Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. GBS Inc. has attempted to identify forward-looking statements by terminology including beliefs, estimates, anticipates, expects, plans, projects, intends, potential, may, could, might, will, should, approximately, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors included in the company's public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. During this conference call, the company may refer to EBITDA, a non-GAAP measure. EBITDA is not and should not be considered an alternative to net income slash loss, income slash loss from operations, or any other measure for determining operating performance. EBITDA is normally calculated by adding back income tax, depreciation, and memorization to net income slash loss. I would now like to turn the floor over to Dr. Stephen Boyages, Interim CEO of GBS Inc. Stephen, please go ahead.

Thank you, and good afternoon, and thank you for joining us on our quarterly business and financial update call today. I hope you've been able to briefly review today's press release. that provided an overview of our recent achievements, important upcoming milestones and financial results for the third quarter ended March 31st, 2022. On today's call, I would like to highlight some key achievements the GBS team has made this quarter. Specifically, our clinical advancements as well as developments in the build-out of our high-tech manufacturing facilities. I'll then turn the call over to Spiro, our chief financial officer, for a review of some key financial metrics, including our preliminary third quarter results and our forecasted cash burn. The prioritisation of clinical development manufacturing bills has remained a key objective for our team in the last quarter, and we're excited to report we've made several advancements supporting our lead asset, that is the saliva-based glucose testing. In March, we announced the Institutional Review Board approval to initiate subject enrollment to the Diabetes Research Institute of Sutter Health for our prospective study to collect coincident samples of oral fluid and blood to evaluate the time course of glucose. This study is expected to enroll approximately 40 adults with type 2 diabetes mellitus and utilizes key collaborators within the molecular diagnostics industry to ensure the integrity and quality control of each sample being collected, being processed at the highest standards possible. We are fortunate to have industry leaders such as Crest Diagnostics and the Johns Hopkins Hospital Department of Pathology evaluating these samples to determine the amount of glucose in oral fluids, venous blood, and capillary blood. Our team at GBS will perform subsequent statistical analysis of the correlation of glucose levels amongst these sample types. Leading the study is Dr. David Klonoff, Medical Director of the Diabetes Research Institute at the MPMC, will be the primary investigator for this study. We believe this is the first step of building a robust clinical portfolio as we expand our pipeline of additional indications to leverage our novel technologies. Turning to our manufacturing achievements this quarter, I'm also very excited to report today that the development plan to commence construction is in its final stages. The University of Newcastle in Australia and GBS have locations identified on their campus and anticipate breaking ground in the back half of next quarter. Last month, we completed the sourcing for critical equipment to ensure build-out timelines are maintained. This has the dual purpose of immediately utilising the equipment in the interests of efficiency to progress development of the biosensor and at the same time commission this equipment in preparation for the facility. Initial delivery of this equipment is expected in June of this year and we look forward to updating investors as these milestones are complete in the coming months and weeks ahead. We believe the need today for developing innovative biosensors for point-of-care monitoring and diagnostic tests which can provide actionable results is core to the healthcare solutions of tomorrow. Our proprietary technologies incorporate non-invasive, real-time, saliva-based testing approaches with accuracy and ease of use not previously available on the market today. Our patients with diabetes have the right to an affordable, convenient and disposable testing option. GBS intends to drive increased compliance and reliable testing solutions, which will in turn provide better outcomes to patients and reduce excessive costs to patients, providers and payers. We remain enthusiastic and committed to driving returns for our stakeholders. Finally, we would like to thank you for your support and look forward to building on our successes in the future. I would now like to turn the call over to our CFO, Spiro Securus, for a more detailed review of our third quarter financials.

Thank you, Spiro.